

Table S1 Comparison between biochemical leak group and CR-POPF group

Variables	All (N=153)	Biochemical leak group (n=47)	CR-POPF group (n=106)	P value
Pancreatic duct dilatation				
No (≤ 4 mm)	94 (61.44)	30 (63.83)	64 (60.38)	0.686
Yes (>4 mm)	59 (38.56)	17 (36.17)	42 (39.62)	
Tumor size				
≤ 4 cm	135 (88.24)	42 (89.36)	93 (87.74)	0.773
>4 cm	18 (11.77)	5 (10.64)	13 (12.26)	
SMI (cm^2/m^2)				
≤ 30 (female), ≤ 40 (male)	84 (54.90)	18 (38.30)	66 (62.26)	0.006*
>30 (female), >40 (male)	69 (45.10)	29 (61.70)	40 (37.74)	
BMI (kg/m^2)	23.44 (20.83, 25.15)	23.18 (20.76, 25.24)	23.437 (21.09, 24.98)	0.860
TG (mmol/L)	1.96 (1.19, 3.07)	1.68 (1.10, 2.91)	2.03 (1.25, 3.10)	0.444
AST/ALT	1.07 (0.84, 1.44)	1.02 (0.84, 1.54)	1.07 (0.85, 1.39)	0.968

Data are presented as median (Q1, Q3) or n (%). *, significance was set at $P < 0.05$. AST, aspartate aminotransferase; ALT, alanine aminotransferase; BMI, body mass index; CR-POPF, clinically relevant pancreatic fistula; SMI, skeletal muscle index; TG, triglyceride.

Table S2 Complications between biochemical leak group and non-POPF group

Postoperative condition	All (N=163)	Non-POPF group (n=116)	Biochemical leak group (n=47)	P value
Bile leakage	6 (3.7)	5 (4.3)	1 (2.1)	0.503
Delayed gastric emptying ^a	20 (12.3)	10 (8.6)	10 (21.3)	0.026*
Hemorrhage	4 (2.5)	3 (2.6)	1 (2.1)	1.000
Intraperitoneal infection with drainage therapy	4 (2.5)	2 (1.7)	2 (4.3)	0.698
Pulmonary complications	11 (6.7)	5 (4.3)	6 (12.8)	0.109
Additional surgery or interventional therapy	3 (1.8)	1 (0.9)	2 (4.3)	0.200
Clavien-Dindo complications				
I-II	53 (32.5)	35 (30.2)	18 (38.3)	0.316
III-V	10 (6.1)	3 (2.6)	7 (14.9)	0.009*

Data are presented as n (%). a, indwelling gastric tube >14 days or indwelling catheterization again. *, significance was set at $P < 0.05$. POPF, postoperative pancreatic fistula.